Dendreon Corporation  

(Public, OTCMKTS:DNDNQ)   Watch this stock  
Find more results for NASDAQ:DNDN
0.0558
-0.0002 (-0.36%)
Mar 4 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.05 - 0.06
52 week 0.04 - 3.28
Open 0.06
Vol / Avg. 1.86M/6.00M
Mkt cap 8.86M
P/E     -
Div/yield     -
EPS -1.06
Shares 158.72M
Beta 1.45
Inst. own 4%
May 11, 2015
Dendreon Corporation Annual Shareholder Meeting (Estimated) Add to calendar
Mar 4, 2015
Q4 2014 Dendreon Corp Earnings Release (Estimated)
  

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -30.18% -104.60%
Operating margin -11.93% -85.65%
EBITD margin - -54.78%
Return on average assets -25.12% -51.37%
Return on average equity - -
Employees 755 -
CDP Score - -

Address

SUITE 3200, 1301 2ND AVE.
SEATTLE, WA 98101
United States - Map
+1-206-2197815 (Phone)

Website links

Description

Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients. The Company's product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers. PROVENGE (sipuleucel-T), is the Company's first commercialized product approved by the United States Food and Drug Administration (FDA), and is a autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. The Company owns worldwide rights for PROVENGE. Other product candidates the Company has under development include its investigational active cellular immunotherapy, DN24-02. The Company completed its Phase I clinical trial in April 2012 to evaluate Transient Receptor Potential, sub-family M (TRPM8).

Officers and directors

Douglas G. Watson Chairman of the Board
Age: 69
Robert L. Crotty President, General Counsel, Secretary
Age: 41
Gregory R. Cox Chief Financial Officer, Treasurer
Age: 49
William Monteith Executive Vice President - Technical Operations
Age: 56
Lindsay Rocco Executive Vice President - Corporate Communications
Age: 35
Andrew S. Sandler M.D. Executive Vice President, Chief Medical Officer
Age: 49
William Jenkinson Chief Marketing Officer, Vice President
Age: 43
Karen E. Brophy Vice President, Head of Human Resources
Age: 51
Silvio Pacheco Vice President, Chief Customer Officer
Age: 48
David L. Urdal Ph.D. Director
Age: 64